This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.
Zacks Industry Outlook Highlights UnitedHealth Group, Cignat, Humana and Centene
by Zacks Equity Research
UnitedHealth Group, Cignat, Humana and Centene are part of the Zacks Industry Outlook article.
4 HMO Stocks in Focus Despite Tech Costs, Nursing Shortage
by Debasmita Chatterjee
A well-performing government business might aid the Medical-HMO industry. However, expenses incurred for technology advancements and a shortage of nurses will dampen margins. Stocks like UNH, CI, HUM and CNC are likely to ride out the industry storms.
Here's What You Should Know From Centene's (CNC) 2023 Outlook
by Zacks Equity Research
Centene's (CNC) board boosts its share buyback program with a new $2-billion fund.
The Zacks Analyst Blog Highlights Chevron, Roche Holding, General Electric, Centene and Carrier Global
by Zacks Equity Research
Chevron, Roche Holding, General Electric, Centene and Carrier Global are included in this Analyst Blog.
Top Analyst Reports for Chevron, Roche & General Electric
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Roche Holding AG (RHHBY) and General Electric Company (GE).
Here's Why Centene (CNC) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Centene (CNC) Invests Nearly $8M to Build Texas Community Center
by Zacks Equity Research
Centene (CNC) collaborates with CHDI to establish a new community center in Texas, reflecting efforts to expand its Managed Care business across the state.
Centene (CNC) Concludes Magellan Rx Divestment to Prime
by Zacks Equity Research
Centene (CNC) completes Magellan Rx divestment within the scheduled time.
Humana (HUM) Down 2.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why You Should Retain Centene (CNC) in Your Portfolio Now
by Zacks Equity Research
Divesting operations like PANTHERx, Magellan Specialty Health and others are going to enable Centene (CNC) to intensify its focus on its core Managed Care business.
Why Is Centene (CNC) Down 1.4% Since Last Earnings Report?
by Zacks Equity Research
Centene (CNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Centene (CNC) to Sell Magellan Arm, To Use Proceeds for Buybacks
by Zacks Equity Research
Centene (CNC) strikes a deal with Evolent to divest Magellan Specialty Health, a Magellan Health arm, to deepen focus on solidifying its core Managed Care business.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
Pediatrix (MD) Down 19% Since Q3 Earnings & Revenue Miss
by Zacks Equity Research
Pediatrix's (MD) Q3 results reflect volume constraints and an elevated expense level. Adjusted EBITDA is now expected within $240-$245 million, down from the earlier view of $260-$270 million.
Should Vanguard MidCap ETF (VO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VO
Why Acadia Healthcare (ACHC) Lost 3% Since Q3 Earnings Release
by Zacks Equity Research
Acadia Healthcare's (ACHC) third-quarter results reflect escalating salaries, wages and benefits. The downside was partly mitigated by rising patient admissions within its U.S. facilities.
Ensign Group (ENSG) Shares Up 2% Despite Q3 Earnings Miss
by Zacks Equity Research
Ensign Group's (ENSG) third-quarter results reflect strength in the Skilled Services segment. A hiked 2022 EPS guidance remains noteworthy. However, escalated expenses are bothersome.
Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CLRG
Tenet Healthcare (THC) Q3 Earnings Beat, Down Y/Y, Shares Drop
by Zacks Equity Research
Tenet Healthcare's (THC) third-quarter results reflect a dismal performance of the Hospital Operations and Other segment as well as continued pressure on patient volumes from the pandemic.
Is IQ Chaikin U.S. Large Cap ETF (CLRG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CLRG
Cigna (CI) Q3 Earnings Top on Evernorth Unit, 2022 EPS View Up
by Zacks Equity Research
Cigna's (CI) third-quarter results reflect strong pharmacy revenues coupled with solid segmental performances. A hiked 2022 EPS outlook is commendable.
Humana (HUM) Q3 Earnings Beat on Strong Individual MA Unit
by Zacks Equity Research
Humana's (HUM) third-quarter earnings gain from solid premiums and membership growth within its individual Medicare Advantage business coupled with a well-performing Healthcare Services segment.
ResMed (RMD) Q1 Earnings In Line, Operating Margin Falls
by Zacks Equity Research
ResMed (RMD) continues to increase its access to semiconductor communications chips.
Amedisys (AMED) Q3 Earnings Miss Estimates, Guidance Cut
by Zacks Equity Research
Within Amedisys (AMED) Home Health and Hospice, the reinstatement of sequestration reduces growth in Q3.